Independent Data Safety Monitoring Board (DSMB) recommends to continue HERACLES study without modification. Lyon, France,…
nboutaouiFebruary 5, 2019
Lyon, France, November 2, 2018 – MaaT Pharma announced today that the company will present…
MaaT PharmaNovember 6, 2018
Microbiome restoration biological drug product to be tested for safety and overall survival impact in…
MaaT PharmaOctober 12, 2018
Results from in silico analysis using MaaT Pharma’s data analysis platform, GutPrint, demonstrate therapeutic rationale…
MaaT PharmaSeptember 18, 2018
MaaT Pharma receives world-wide exclusive license to technology co-developed with hematology and gastroenterology departments of…
MaaT PharmaJune 21, 2018
MaaT Pharma, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase…
MaaT PharmaMarch 5, 2018
The French Microbiome company completed its first clinical study proving that Autologous Fecal Microbiota Transfer…
MaaT PharmaNovember 30, 2017
Maat Pharma has reached the target number of patients to be treated in its first…
MaaT PharmaJuly 20, 2017